IDSA Guideline Update: Antivirals for Mild to Moderate Covid-19

The risk for severe disease and mortality associated with Covid-19 decreased over time due to increased population immunity. A panel of experts recently reviewed the evidence for treating mild to moderate Covid-19 (i.e., no hypoxia or need for supplemental oxygen) and provided guidance on the use of nirmatrelvir–ritonavir, remdesivir, and molnupiravir. Recommendations are based on the risk level for progression to severe disease; “high” risk (e.g., age ≥75 years) is distinguished from “increased” (but not high) risk (e.g., ag…